International Journal of Hematology

, Volume 106, Issue 5, pp 655–665 | Cite as

Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study

  • Dai Maruyama
  • Kensei Tobinai
  • Michinori Ogura
  • Toshiki Uchida
  • Kiyohiko Hatake
  • Masafumi Taniwaki
  • Kiyoshi Ando
  • Kunihiro Tsukasaki
  • Takashi Ishida
  • Naoki Kobayashi
  • Kenichi Ishizawa
  • Yoichi Tatsumi
  • Koji Kato
  • Toru Kiguchi
  • Takayuki Ikezoe
  • Eric Laille
  • Tokihiro Ro
  • Hiromi Tamakoshi
  • Sanae Sakurai
  • Tomoko Ohtsu
Original Article


This phase I/II multicenter study evaluated romidepsin treatment in Japanese patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL). Patients aged ≥20 years received romidepsin via a 4-h intravenous infusion on days 1, 8, and 15 of each 28-day cycle. Phase I used a 3 + 3 design to identify any dose-limiting toxicity (DLT) for regimens of romidepsin 9 and 14 mg/m2. The primary endpoints for phase I and II were DLT and overall response rate (ORR), respectively. Intent-to-treat patients were those who received ≥1 romidepsin dose (PTCL, n = 48; CTCL, n = 2). In phase I, none of the patients (n = 3, 9 mg/m2; n = 6, 14 mg/m2) exhibited DLT. In phase II, 40 patients with PTCL were treated with 14 mg/m2 romidepsin. The most common treatment-emergent grade ≥3 adverse events were lymphopenia (74%), neutropenia (54%), leukopenia (46%), and thrombocytopenia (38%). Patients in phase II showed a 43% ORR, including 25% complete responses. Median progression-free survival was 5.6 months and median duration of response was 11.1 months. This phase I/II study identified a well-tolerated dose of romidepsin, with an acceptable toxicity profile and clinically meaningful efficacy in Japanese patients with relapsed/refractory PTCL. Identifier NCT01456039.


Cutaneous T-cell lymphoma Japanese Peripheral T-cell lymphoma Relapsed or refractory Romidepsin 



All authors performed and/or designed the research study, analyzed the data, contributed to the development and revision of the manuscript, and approved the final version for submission. The authors thank the patients, their family members, and collaborators from participating institutions and Celgene Corporation. Thank you to Norio Komatsu, M.D., Ph.D., for providing medical expertise; Kazuma Ohyashiki, M.D., Ph.D., Jin Takeuchi, M.D., Ph.D., and Noriko Usui, M.D., who served on the efficacy and safety evaluation committee (ESEC); Takashi Terauchi, M.D., Ukihide Tateishi, M.D., and Mitsuaki Tatsumi, M.D., who served on the Independent Radiological Review Committee (IRRC); Yoshihiro Matsuno, M.D., Ph.D., Akiko Maeshima, M.D., Ph.D., and Kouichi Ohshima, M.D., Ph.D., who were the central pathologists for the study; Masaaki Shoji, M.D., who was the cardiologist for the study; and Junji Suzumiya, M.D., Ph.D., who served as an independent efficacy reviewer. Medical writing support was provided by Bio Connections LLC, and funded by Celgene Corporation; the authors were fully responsible for content and editorial decisions for this manuscript.

Compliance with ethical standards

Conflict of interest

D.M. reports personal fees from Celgene during the conduct of the study; and outside the submitted work, honoraria and research funding from Takeda, Janssen, Eisai, Celgene, Kyowa Hakko Kirin, Ono, Mundipharma, and Chugai; research funding from GlaxoSmithKline, Servier, AbbVie, and MSD; and honoraria from Biomedis International, sanofi, Fujifilm, and Mochida Pharmaceutical Co. Ltd. K.To. reports grants and personal fees from Eisai, Takeda, Mundipharma, Kyowa Hakko Kirin, and Celgene; personal fees from HUYA Bioscience International during the conduct of the study; and outside the submitted work, personal fees from Zenyaku Kogyo; grants and personal fees from Janssen, Chugai Pharma, and Ono Pharmaceutical; and grants from GlaxoSmithKline, Servier, and AbbVie. M.O. reports research funding from SymBio and Celltrion; honoraria from AstraZeneca, Takeda, and Celgene; and advisory board personal fees from Mundipharma, MeijiSeika Pharma, and Celltrion outside of the submitted work. K.H. reports relationships/conditions/circumstances that may influence this work from AbbVie, Gilead, Celgene, Solasia, Pfizer, BMS, Janssen, Ono, and Chugai. K.Ts. reports grants from Celgene, Takeda, MundiPharma, and Chugai; and personal lecture fees from Zennyakukogyo, HUYA Biosciences, Chugai, and Kyowa Kirin outside of the submitted work. T.Is. reports personal fees from Celgene K.K. during the conduct of the study; and outside of the submitted work grants from Kyowa Hakko Kirin Co. Ltd, Bayer Pharma AG, and J-pharma Co. Ltd; and honoraria from Kyowa Hakko Kirin Co. Ltd. K.Is. reports grants and personal fees from Kyowa Kirin and Takeda during the conduct of the study; and personal fees from Cyugai, Janssen, Novartis, Ono, and Pfizer outside the submitted work. E.L., T.R., H.T., S.S., and T.O. are employed by and have received stock ownership from Celgene Corporation. T.U., K.A., M.T., N.K., Y.T., K.K., T.K., and T.Ik., have no relevant financial relationships to disclose. The study was designed under the responsibility of Celgene Corporation; the study was funded by Celgene K. K. (Tokyo, Japan); Romidepsin was provided by Celgene K.K. (Tokyo, Japan). Celgene K. K. (Tokyo, Japan) collected and analyzed the data and contributed to the interpretation of the study. All authors had full access to all of the data in the study and had final responsibility for the decision to submit for publication.


  1. 1.
    Karlin L, Coiffier B. The changing landscape of peripheral T-cell lymphoma in the era of novel therapies. Semin Hematol. 2014;51:25–34.CrossRefPubMedGoogle Scholar
  2. 2.
    Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30.CrossRefPubMedGoogle Scholar
  3. 3.
    Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117:3402–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31:1970–6.CrossRefPubMedGoogle Scholar
  5. 5.
    SEER Cancer Statistics Factsheets: Non-Hodgkin Lymphoma. National Cancer Institute. Bethesda, MD. Accessed 17 Jan 2017.
  6. 6.
    Suzuki R. Guideline for T/NK-cell lymphoma. Rinsho Ketsueki. 2013;54:1764–9.PubMedGoogle Scholar
  7. 7.
    Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Lunning MA. Treatment of peripheral T-cell lymphoma: many shades of gray. Oncology (Williston Park). 2015;29:545–50.PubMedGoogle Scholar
  9. 9.
    Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32:1157–63.CrossRefPubMedGoogle Scholar
  10. 10.
    Zinzani PL, Karlin L, Radford J, Caballero D, Fields P, Chamuleau ME, et al. European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma. Haematologica. 2016;101:e407–10.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo). 1994;47:315–23.CrossRefGoogle Scholar
  12. 12.
    Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo). 1994;47:301–10.CrossRefGoogle Scholar
  13. 13.
    Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res. 1998;241:126–33.CrossRefPubMedGoogle Scholar
  14. 14.
    Hartlapp I, Pallasch C, Weibert G, Kemkers A, Hummel M, Re D. Depsipeptide induces cell death in Hodgkin lymphoma-derived cell lines. Leuk Res. 2009;33:929–36.CrossRefPubMedGoogle Scholar
  15. 15.
    Valdez BC, Brammer JE, Li Y, Murray D, Liu Y, Hosing C, et al. Romidepsin targets multiple survival signaling pathways in malignant T cells. Blood Cancer J. 2015;5:e357.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Graham C, Tucker C, Creech J, Favours E, Billups CA, Liu T, et al. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res. 2006;12:223–34.CrossRefPubMedGoogle Scholar
  17. 17.
    Piekarz RL, Robey RW, Zhan Z, Kayastha G, Sayah A, Abdeldaim AH, et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood. 2004;103:4636–43.CrossRefPubMedGoogle Scholar
  18. 18.
    Sasakawa Y, Naoe Y, Inoue T, Sasakawa T, Matsuo M, Manda T, et al. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol. 2002;64:1079–90.CrossRefPubMedGoogle Scholar
  19. 19.
    Murata M, Towatari M, Kosugi H, Tanimoto M, Ueda R, Saito H, et al. Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells. Jpn J Cancer Res. 2000;91:1154–60.CrossRefPubMedGoogle Scholar
  20. 20.
    Kosugi H, Ito M, Yamamoto Y, Towatari M, Ito M, Ueda R, et al. In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD/Shi-scid/scid mice. Jpn J Cancer Res. 2001;92:529–36.CrossRefPubMedGoogle Scholar
  21. 21.
    Sato N, Ohta T, Kitagawa H, Kayahara M, Ninomiya I, Fushida S, et al. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int J Oncol. 2004;24:679–85.PubMedGoogle Scholar
  22. 22.
    Klisovic DD, Katz SE, Effron D, Klisovic MI, Wickham J, Parthun MR, et al. Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines. Investig Ophthalmol Vis Sci. 2003;44:2390–8.CrossRefGoogle Scholar
  23. 23.
    Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, Kang MH, et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol. 2002;2:325–32.CrossRefPubMedGoogle Scholar
  24. 24.
    Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002;8:718–28.PubMedGoogle Scholar
  25. 25.
    Amiri-Kordestani L, Luchenko V, Peer CJ, Ghafourian K, Reynolds J, Draper D, et al. Phase I trial of a new schedule of romidepsin in patients with advanced cancers. Clin Cancer Res. 2013;19:4499–507.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117:5827–34.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014;7:11.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.CrossRefPubMedGoogle Scholar
  30. 30.
    JCOG-LSG. JCOG-LSG manual of clinical research for lymphoma and myeloma. 1st ed. Tokyo, Japan: The Japan Foundation for Aging and Health; 2003. p. 68–73.Google Scholar
  31. 31.
    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.CrossRefPubMedGoogle Scholar
  32. 32.
    Hashimoto K, Kobayashi Y, Asakura Y, Mori M, Azuma T, Maruyama D, et al. Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy. Leuk Lymphoma. 2010;51:1816–21.CrossRefPubMedGoogle Scholar
  33. 33.
    Swerdlow SH, Campo E, Harris NLE. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.Google Scholar
  34. 34.
    Kim SJ, Kim JH, Ki CS, Ko YH, Kim JS, Kim WS. Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin. Ann Oncol. 2016;27:508–13.CrossRefPubMedGoogle Scholar
  35. 35.
    Bates SE, Zhan Z, Steadman K, Obrzut T, Luchenko V, Frye R, et al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol. 2010;148:256–67.CrossRefPubMedGoogle Scholar
  36. 36.
    Woo S, Gardner ER, Chen X, Ockers SB, Baum CE, Sissung TM, et al. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009;15:1496–503.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    O’Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29:1182–9.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer. 2013;49:2869–76.CrossRefPubMedGoogle Scholar
  39. 39.
    Ogura M, Imaizumi Y, Uike N, Asou N, Utsunomiya A, Uchida T, et al. Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. Lancet Haematol. 2016;3:e107–18.CrossRefPubMedGoogle Scholar
  40. 40.
    Tsukasaki K, Tobinai K, Uchida T, Maeda Y, Shibayama H, Nagai H, et al. Phase 1/2 study of forodesine in patients with relapsed peripheral T-cell lymphoma. J Clin Oncol. 2016. doi:10.1200/JCO.2016.34.15 PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  • Dai Maruyama
    • 1
  • Kensei Tobinai
    • 1
  • Michinori Ogura
    • 2
    • 3
  • Toshiki Uchida
    • 3
  • Kiyohiko Hatake
    • 4
  • Masafumi Taniwaki
    • 5
  • Kiyoshi Ando
    • 6
  • Kunihiro Tsukasaki
    • 7
  • Takashi Ishida
    • 8
  • Naoki Kobayashi
    • 9
  • Kenichi Ishizawa
    • 10
    • 11
  • Yoichi Tatsumi
    • 12
  • Koji Kato
    • 13
  • Toru Kiguchi
    • 14
  • Takayuki Ikezoe
    • 15
    • 16
  • Eric Laille
    • 17
  • Tokihiro Ro
    • 18
  • Hiromi Tamakoshi
    • 18
  • Sanae Sakurai
    • 18
  • Tomoko Ohtsu
    • 18
  1. 1.Department of HematologyNational Cancer Center HospitalTokyoJapan
  2. 2.Department of HematologyTokai Central HospitalGifuJapan
  3. 3.Department of Hematology and OncologyNagoya Daini Red Cross HospitalAichiJapan
  4. 4.Department of Hematology and OncologyThe Cancer Institute Hospital of Japanese Foundation for Cancer ResearchTokyoJapan
  5. 5.Department of HematologyKyoto Prefectural University of MedicineKyotoJapan
  6. 6.Department of Hematology/OncologyTokai University School of MedicineKanagawaJapan
  7. 7.Department of Hematology and OncologyNational Cancer Center Hospital EastChibaJapan
  8. 8.Department of Hematology and OncologyNagoya City University Graduate School of Medical SciencesAichiJapan
  9. 9.Department of HematologySapporo Hokuyu HospitalHokkaidoJapan
  10. 10.Department of Hematology and RheumatologyTohoku University HospitalMiyagiJapan
  11. 11.Hematology and Cell TherapyYamagata University Faculty of MedicineYamagataJapan
  12. 12.Department of Hematology and RheumatologyKinki University Hospital, Faculty of MedicineOsakaJapan
  13. 13.Department of Hematology and OncologyKyushu University HospitalFukuokaJapan
  14. 14.Department of HematologyChugoku Central HospitalHiroshimaJapan
  15. 15.Department of Hematology and Respiratory MedicineKochi Medical School HospitalKochiJapan
  16. 16.Department of HematologyFukushima Medical University School of MedicineFukushimaJapan
  17. 17.Celgene CorporationSummitUSA
  18. 18.Celgene K.K.TokyoJapan

Personalised recommendations